Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Homo sapiens | isocitrate dehydrogenase 1 (NADP+), soluble | Starlite/ChEMBL | No references |
Homo sapiens | parathyroid hormone 1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | hypothetical protein | 0.0082 | 0.3573 | 0.3573 |
Schistosoma mansoni | hypothetical protein | 0.0038 | 0.1075 | 0.1075 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 0.7069 | 0.7069 |
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0038 | 0.1075 | 0.1075 |
Schistosoma mansoni | tar DNA-binding protein | 0.0196 | 1 | 1 |
Echinococcus multilocularis | cadherin EGF LAG seven pass G type receptor | 0.0038 | 0.1075 | 0.1075 |
Schistosoma mansoni | hypothetical protein | 0.0038 | 0.1075 | 0.1075 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0082 | 0.3573 | 0.3573 |
Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0038 | 0.1075 | 0.1075 |
Plasmodium vivax | isocitrate dehydrogenase [NADP], mitochondrial, putative | 0.0019 | 0 | 0.5 |
Echinococcus granulosus | tar DNA binding protein | 0.0196 | 1 | 1 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 0.7069 | 0.7069 |
Mycobacterium tuberculosis | Probable isocitrate dehydrogenase [NADP] Icd1 (oxalosuccinate decarboxylase) (IDH) (NADP+-specific ICDH) (IDP) | 0.0019 | 0 | 0.5 |
Echinococcus granulosus | GPCR family 2 | 0.0038 | 0.1075 | 0.1075 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0196 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0038 | 0.1075 | 0.1075 |
Echinococcus multilocularis | GPCR, family 2 | 0.0038 | 0.1075 | 0.1075 |
Echinococcus granulosus | diuretic hormone 44 receptor GPRdih2 | 0.0038 | 0.1075 | 0.1075 |
Plasmodium falciparum | isocitrate dehydrogenase [NADP], mitochondrial | 0.0019 | 0 | 0.5 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.012 | 0.5726 | 0.5726 |
Schistosoma mansoni | tar DNA-binding protein | 0.0196 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.012 | 0.5726 | 0.5726 |
Trypanosoma brucei | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0019 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0038 | 0.1075 | 0.1075 |
Toxoplasma gondii | isocitrate dehydrogenase | 0.0019 | 0 | 0.5 |
Trypanosoma cruzi | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0019 | 0 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0196 | 1 | 1 |
Leishmania major | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0019 | 0 | 0.5 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.012 | 0.5726 | 0.5726 |
Loa Loa (eye worm) | hypothetical protein | 0.0082 | 0.3573 | 0.3573 |
Trypanosoma cruzi | isocitrate dehydrogenase, putative | 0.0019 | 0 | 0.5 |
Echinococcus granulosus | cadherin EGF LAG seven pass G type receptor | 0.0038 | 0.1075 | 0.1075 |
Echinococcus multilocularis | tar DNA binding protein | 0.0196 | 1 | 1 |
Trypanosoma brucei | isocitrate dehydrogenase, putative | 0.0019 | 0 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0196 | 1 | 1 |
Brugia malayi | MH2 domain containing protein | 0.0144 | 0.7069 | 0.7069 |
Brugia malayi | Latrophilin receptor protein 2 | 0.0038 | 0.1075 | 0.1075 |
Toxoplasma gondii | isocitrate dehydrogenase | 0.0019 | 0 | 0.5 |
Echinococcus multilocularis | diuretic hormone 44 receptor GPRdih2 | 0.0038 | 0.1075 | 0.1075 |
Schistosoma mansoni | tar DNA-binding protein | 0.0196 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0038 | 0.1075 | 0.1075 |
Schistosoma mansoni | tar DNA-binding protein | 0.0196 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0196 | 1 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.012 | 0.5726 | 0.5726 |
Loa Loa (eye worm) | RNA binding protein | 0.0196 | 1 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0196 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 7.9433 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 14.581 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 17.7828 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 17.7828 uM | PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PubChem BioAssay. qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.